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Introduction
Ovarian follicular development lies with the interaction
between pituitary gonadotropins, follicle stimulating
hormone and luteinizing hormone (and glucocorticoid
hormone and prolactin in some species), and intraovar-
ian factors such as steroid, cytokines and other growth
factors.1 Among these, prostaglandins (PGs) possess
vasoactive, mitogenic, and differentiating properties
and are implicated in various female reproductive func-
tions.2 In particular, PGs have been shown to play key
roles in ovarian physiology, the periovulatory period,
and female reproduction.3 Several studies have sug-
gested a role for PGs in the maintenance and function
of the cumulus–oocyte complex (COC).4 PGE2 was
one of the earliest substances shown to induce cumu-
lus expansion in vitro.5 Additionally, COCs obtained
from rats and mice after superovulation synthesize
PGE1, PGE2 and PGF2α.5,6 Therefore, any drug that
blocks synthesis of PGs would affect female reproduc-
tive function. In fact, it is reported that high doses of
indomethacin (an inhibitor of both cyclooxygenase-1
[COX-1] and -2 [COX-2], one of the nonsteroidal anti-
inflammatory drugs [NSAIDs]) or a “specific” COX-2
inhibitor (NS-398) can block ovulation in rats.3,7 In
addition, treatment of COCs with indomethacin greatly
reduces the in vitro fertilization rate of oocytes, and
this effect is reversed if PGE1 and PGE2 are added to
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the media in the presence of indomethacin.6 These
data suggest that PGs may be critical for maintaining
an optimal microenvironment for oocyte survival and
fertilization.
However, although use of low-dose indomethacin
can abolish ovarian PGE2 synthesis, low-dose
indomethacin failed to affect ovulation.8 In contrast,
high-dose indomethacin resulted in significant inhibi-
tion of ovulation.8 It was also noted that absence of
COX-2 in mice led to defects in ovulation, fertilization,
and implantation,9 suggesting that COX-2 enzyme may
play an important role in female reproduction. Selective
COX-2 inhibitors are commonly used in clinical prac-
tice, including for the management of dysmenorrhea,
menorrhagia or other rheumatism, all of which often
attack women in reproductive age. In this study, a low
dose of the selective NSAID COX-2 inhibitor, cele-
coxib, was used to evaluate its effects on the reproduc-
tive function of female mice.
Methods
All mouse experiments (BALB/C strain; weight, 20–
30 g) were approved by the Institutional Animal Care
and Use Committee of Taipei Veterans General Hos-
pital. Animals were housed in an air-conditioned room
with free access to a commercial pellet diet and tap
water. In order to maintain stable biological rhythms,
12 hours of artificial light and 12 hours of darkness
were provided.
Superovulation with exogenous gonadotropins
To assess the ovarian function of female mice treated
with low-dose celecoxib, we induced superovulation
with exogenous gonadotropins in immature female
mice (weight, 20–25 g) at 25 days of age to determine
the oocyte production per female. Reasons for using
immature female mice for the superovulation test
included: (1) to avoid the possible effect of endoge-
nous hormone inducing follicle growth or ovulation
in the mice; and (2) to ignore the cyclic change of
female mice after sexual maturation. This approach
can be found in the literature.10–13 Superovulation
assays11,12 were carried out on female mice (n = 24)
feeding with COX-2 inhibitor (n = 16) or not (n = 8)
at 25 days of age. The COX-2 inhibitor, celecoxib
(Celebrex®; Pfizer Inc., New York, NY, USA), at doses
of 3 mg/kg (n = 8) and 5 mg/kg (n = 8) was adminis-
tered by oral intubation once daily to each group ini-
tially from 3 days before entering ovulation induction
to the day of ovulation induction for a total of 4 days.
The superovulation protocol consisted of a single
intraperitoneal (IP) injection with 5 IU pregnant mare’s
serum gonadotropin (PMSG) (Sigma, St Louis, MO,
USA) followed 48 hours later with IP 7.5 IU human
chorionic gonadotropin (hCG) (Sigma) injection. The
animals were sacrificed 20 hours after hCG injection,
and the ovaries, oviduct, uterus and vagina removed
to 1X phosphate-buffered saline (PBS) (pH 7.4) for
washing. The oviduct–ovary complexes were excised
and placed into 2 mL Dulbecco’s modified Eagle’s
medium (DMEM) containing 25 U/mL penicillin,
25U/mL streptomycin and 20% fetal calf serum (FCS).
After separating the ovary (preparing for ovarian his-
tology and follicle counting) from the oviduct–ovary
complex, the oviducts were removed to IVF dishes
(Corning Inc., Corning, NY, USA) with DMEM
containing 10% FCS, supplemented with 0.3%
hyaluronidase (Sigma). The oocyte/cumulus mass was
surgically extracted from the oviduct.
Fertility of female mice
Eight 10–11-week-old female mice (weight, 25–30 g)
were subjected to continuous mating studies. Celecoxib
3 mg/kg (n = 4) was administered by oral intubation
once daily from 25 days of age until the end of the
study. Two female mice were housed with 1 fertile male
mouse aged 4–6 weeks, and the male mice were rotated
weekly. Cages were monitored daily, and the numbers
of pups and litters were recorded.
Statistical analysis
Quantitative data were expressed as mean ± standard
error of the mean and analyzed by Student’s 2-tailed
unpaired t test using Microsoft Excel 2003. Fisher’s
exact test was used for the analysis of qualitative data.
Statistical significance was set at p < 0.05.
Results
No effect on ovulation capacity
Results from the 24 mice (n = 8 for each group) indi-
cated that oocyte number was not significantly differ-
ent between female mice treated with either 3 mg/kg
or 5 mg/kg celecoxib, and placebo (21.4 ± 2.5, 21.5 ±
3.3, 23.3 ± 3.8, respectively), indicating that the ovu-
lation function of the female mice were not affected by
doses of 3 mg/kg and 5 mg/kg Celebrex®.
No effect on female fertility
We employed a continuous mating study using sexually
mature female mice (n = 4 for each group) at 10–11
weeks of age and known fertile male mice. After 12
weeks of mating, the litter size of the female mice treated
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with celecoxib was not significantly different (8.2 ±
1.3 pups/litter) from that of female mice treated with
placebo (8.3±1.2pups/litter). In addition, female mice
treated with celecoxib had an average of 2.8 ± 0.5 litters
in a 12-week period, which was similar to that of female
mice treated with placebo (3.0 ± 0.8 litters/female).
Discussion
The COX enzyme complex, a key enzyme in the syn-
thesis of PGs from arachidonic acid, consists of at
least 2 enzymes existing as distinctly regulated forms
expressed by separate genes and differing in distribu-
tion, regulation, and expression.14,15 COX-1 is consti-
tutively expressed in all tissues and regulates the action
of PGs, whereas COX-2 is induced in immune cells and
other tissues following diverse stimuli, such as mito-
gens, proinflammatory cytokines, growth factors, and
tumor promoters.16–20 NSAIDs, acting largely through
inhibition of COX, are widely used as anti-inflammatory
agents and as analgesia for various disorders.21 Due 
to nonspecific inhibition of the COX family, NSAIDs
possess many side effects since they block the consti-
tutive function of COX-1. Because COX-2 is prima-
rily responsible for increased PG production during
inflammation, this isoform is the target for development
of selective anti-inflammatory drugs.2 Development of
specific antagonists to COX-2 has permitted the use of
potent anti-PG agents without many of the side effects
commonly attributed to the nonspecific NSAIDs.22
The processes of ovulation and implantation are
considered analogous to proinflammatory responses;
thus, participation of PGs in these events has been
speculated.23 For example, PGs are considered to par-
ticipate in follicular rupture during ovulation.2 This is
consistent with gonadotropin-mediated induction of
COX-2 in ovarian follicles preceding ovulation.24 There
is evidence to indicate that COX inhibitors have major
effects on ovulation and other reproductive processes,
including fertilization, decidualization, implantation
and parturition, and that they are a link to reversible
female infertility.21 However, COX-2 also regulates PGs,
which are important in many reproductive processes.14
Selective blockage of COX-2 using pharmacologic
agents reduces PG production and ovulation both 
in vivo and in vitro in the rat.21 However, in this study
of a low-dose COX-2 inhibitor in female mice, we failed
to demonstrate any impairment in ovulation since
oocyte number was not statistically significantly dif-
ferent between female mice treated with 3 mg/kg or
5 mg/kg celecoxib and placebo (21.4 ±2.5, 21.5 ±3.3,
23.3 ± 3.8, respectively).
In clinical practice, Pall et al studied the effects of
the selective COX-2 inhibitor, rofecoxib, on the ovar-
ian function of women.25 The average maximum pre-
ovulatory follicle diameter in women taking rofecoxib
was larger than that in the placebo group (30 mm vs.
21 mm). In addition, 4 out of 6 women taking rofe-
coxib showed delayed follicle rupture (> 48 hours after
the LH peak), which is characteristic of luteinized
unruptured follicle syndrome (LUFS), and the phe-
nomenon disappeared when the medication was dis-
continued,25 suggesting that the clinical implications
of COX-2 inhibition in human fertility are important.
Thus, it is clear that the critical role of PGs in repro-
ductive processes, especially ovulation, can be regu-
lated by COX-2. The implications of these findings
for women who are attempting to become pregnant
and who are taking COX-2 inhibitors are important
because there is increasing evidence of the potential
danger of these drugs. These drugs may prevent or
delay ovulation, with no change in endocrine markers
of ovulation, such as progesterone levels, with the
resulting luteinized unruptured follicle discovered only
by ultrasonography and LH evaluation. In contrast, the
low-dose effect may be different from the above find-
ing because the recent report from Moon et al shows
the benefit of using a low dose of NSAID when per-
forming assisted reproductive technique, because treat-
ment with piroxicam before embryo transfer increases
the pregnancy rate after in vitro fertilization and embryo
transfer.26 Our study agreed with the latter finding, sug-
gesting that low-dose NSAID use may be safe, although
we did not apply this strategy in a human study.
COX-2 is also expressed in the luminal epithelium
and underlying stromal cells solely at the site of blas-
tocyst attachment.2 Using the delayed implantation
model, this study also established that the expression
of COX-2 in the receptive uterus requires the presence
of active blastocysts, suggesting that COX-2 expression
during the attachment reaction is critical to implan-
tation.27 Indeed, gene targeting experiments have
demonstrated that COX-2-derived PGs are essential
for implantation and decidualization.9 However, from
this study, COX-2 inhibitor may be safe if the dose is
low because we clearly demonstrated that low-dose
COX-2 inhibitor of ≤ 5 mg/kg celecoxib per day did
not seem to affect the normal fertility of female mice,
suggesting that implantation may not be impaired when
using a low dose of COX-2 inhibitor.
Since differences exist between primates and other
species in the sites and timing of COX-2 expression 
in the ovary, COX-2 inhibitors may produce different
results in these species. In addition, emerging evidence
shows that COX-2 inhibitors may impair fertilization,
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implantation, and maintenance of pregnancy. From this
study, we found that low-dose COX-2 inhibitor did
not affect fertilization, implantation and maintenance
of pregnancy in a mouse model. Overall, the thera-
peutic window between pain relief and fertility impair-
ment in using COX-2 inhibitors in clinical practice is
worthy of further investigation.
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